carvedilol has been researched along with Cardiac Arrest, Sudden in 27 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "We explored whether vascular protection by carvedilol could contribute to its superior effects in the treatment of heart failure (HF) compared with metoprolol tartrate in the COMET (Carvedilol Or Metoprolol European Trial) study." | 9.12 | Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET. ( Cleland, JG; Di Lenarda, A; Komajda, M; Lukas, MA; Metra, M; Moullet, C; Poole-Wilson, PA; Remme, WJ; Scherhag, A; Spark, P; Swedberg, K; Torp-Pedersen, C, 2007) |
| "Uncertainty persists about the safety and efficacy of amiodarone for the management of heart failure." | 9.12 | The safety of amiodarone in patients with heart failure. ( Cleland, JG; Di Lenarda, A; Komajda, M; Lukas, MA; Metra, M; Moullet, C; Poole-Wilson, PA; Remme, W; Scherhag, A; Spark, P; Swedberg, K; Torp-Pedersen, C, 2007) |
| "In a randomized double-blind design, 3029 patients with chronic congestive heart failure requiring diuretic therapy and with left ventricular dysfunction were randomized to treatment with carvedilol (n = 1511) or metoprolol tartrate (n = 1518) and titrated to target doses of 25 mg of carvedilol twice daily or 50 mg of metoprolol tartrate twice daily." | 9.11 | Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure--COMET. ( Cleland, JG; Di Lenarda, A; Hanrath, P; Komajda, M; Lutiger, B; Metra, M; Poole-Wilson, PA; Remme, WJ; Scherhag, A; Skene, A; Swedberg, K; Torp-Pedersen, C, 2005) |
| "We explored whether vascular protection by carvedilol could contribute to its superior effects in the treatment of heart failure (HF) compared with metoprolol tartrate in the COMET (Carvedilol Or Metoprolol European Trial) study." | 5.12 | Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET. ( Cleland, JG; Di Lenarda, A; Komajda, M; Lukas, MA; Metra, M; Moullet, C; Poole-Wilson, PA; Remme, WJ; Scherhag, A; Spark, P; Swedberg, K; Torp-Pedersen, C, 2007) |
| "Uncertainty persists about the safety and efficacy of amiodarone for the management of heart failure." | 5.12 | The safety of amiodarone in patients with heart failure. ( Cleland, JG; Di Lenarda, A; Komajda, M; Lukas, MA; Metra, M; Moullet, C; Poole-Wilson, PA; Remme, W; Scherhag, A; Spark, P; Swedberg, K; Torp-Pedersen, C, 2007) |
| "In a randomized double-blind design, 3029 patients with chronic congestive heart failure requiring diuretic therapy and with left ventricular dysfunction were randomized to treatment with carvedilol (n = 1511) or metoprolol tartrate (n = 1518) and titrated to target doses of 25 mg of carvedilol twice daily or 50 mg of metoprolol tartrate twice daily." | 5.11 | Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure--COMET. ( Cleland, JG; Di Lenarda, A; Hanrath, P; Komajda, M; Lutiger, B; Metra, M; Poole-Wilson, PA; Remme, WJ; Scherhag, A; Skene, A; Swedberg, K; Torp-Pedersen, C, 2005) |
| "Carvedilol is an adrenergic antagonist with nonselective beta- and a1-receptor blocking properties that has demonstrated significant clinical benefit in the management of patients with heart failure and in the post-myocardial infarction setting." | 4.82 | Carvedilol: beta-blockade and beyond. ( Gheorghiade, M; Stroe, AF, 2004) |
| "n 1987 the results of the Consensus study were published, and showed that enalapril, an angiotensin convertor enzyme inhibitor (ACEI), was able to modify the clinical course of the heart failure syndrome thereby reducing mortality." | 4.81 | [Clinical trials on heart failure]. ( Cosín Aguilar, J; Hernándiz Martínez, A, 2001) |
| "The effects of carvedilol and metoprolol succinate on appropriate and inappropriate implantable cardioverter defibrillator (ICD) therapy in patients with heart failure with reduced ejection fraction (HFrEF) are not fully understood." | 3.91 | A comparison of anti-arrhythmic efficacy of carvedilol vs metoprolol succinate in patients with implantable cardioverter-defibrillators. ( Alqam, B; Ayan, M; Cross, M; Gheith, Z; Habash, F; Paydak, H; Vallurupalli, S, 2019) |
| "Baroreflex sensitivity was assessed in 287 patients with history of myocardial infarction and left ventricular ejection fraction < or =40% by phenylephrine test and was found to be depressed (4." | 3.72 | [Correction of baroreflex sensitivity impairment and efficacy of prevention of sudden arrhythmic death in patients with postinfarction left ventricular dysfunction]. ( Bozhko, AA; Kanopskiĭ, SG; Staritskiĭ, AG, 2004) |
| "Hypertension is a major influence on the development of LVH." | 2.43 | Ventricular hypertrophy and hypertension: prognostic elements and implications for management. ( Devereux, RB; Krauser, DG, 2006) |
| "Carvedilol treatment was a strong predictor for being on target dose of BB at time of implant, as was treatment with angiotensin-converting enzyme inhibitors and/or spironolactone, no history of myocardial infarction, younger age and less pronounced heart failure symptoms." | 1.48 | The use of guideline recommended beta-blocker therapy in primary prevention implantable cardioverter defibrillator patients: insight from Danish nationwide registers. ( Gislason, GH; Johansen, JB; Jøns, C; Nielsen, JC; Petersen, HH; Riahi, S; Ruwald, AC; Torp-Pedersen, C; Vinther, M, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (7.41) | 18.2507 |
| 2000's | 20 (74.07) | 29.6817 |
| 2010's | 4 (14.81) | 24.3611 |
| 2020's | 1 (3.70) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, JG | 1 |
| Dai, SP | 1 |
| Liu, H | 1 |
| Xu, ZS | 1 |
| Ruwald, AC | 2 |
| Gislason, GH | 2 |
| Vinther, M | 2 |
| Johansen, JB | 2 |
| Nielsen, JC | 2 |
| Petersen, HH | 1 |
| Torp-Pedersen, C | 5 |
| Riahi, S | 2 |
| Jøns, C | 2 |
| Philbert, BT | 1 |
| Ayan, M | 1 |
| Habash, F | 1 |
| Alqam, B | 1 |
| Gheith, Z | 1 |
| Cross, M | 1 |
| Vallurupalli, S | 1 |
| Paydak, H | 1 |
| Susa, T | 1 |
| Kobayashi, S | 1 |
| Tanaka, T | 1 |
| Murakami, W | 1 |
| Akashi, S | 1 |
| Kunitsugu, I | 1 |
| Okuda, S | 1 |
| Doi, M | 1 |
| Wada, Y | 1 |
| Nao, T | 1 |
| Yamada, J | 1 |
| Ueyama, T | 1 |
| Okamura, T | 1 |
| Yano, M | 1 |
| Matsuzaki, M | 1 |
| Sinagra, G | 1 |
| Perkan, A | 1 |
| Cherubini, A | 1 |
| Salvatore, L | 1 |
| Di Lenarda, A | 4 |
| Isnard, R | 1 |
| Coca, SG | 1 |
| Buller, GK | 1 |
| Stroe, AF | 1 |
| Gheorghiade, M | 1 |
| Kanopskiĭ, SG | 1 |
| Staritskiĭ, AG | 1 |
| Bozhko, AA | 1 |
| Poole-Wilson, PA | 3 |
| Swedberg, K | 3 |
| Cleland, JG | 3 |
| Hanrath, P | 1 |
| Komajda, M | 3 |
| Lutiger, B | 1 |
| Metra, M | 3 |
| Remme, WJ | 2 |
| Scherhag, A | 3 |
| Skene, A | 1 |
| Reiffel, JA | 1 |
| Kowey, PR | 1 |
| Paperini, L | 1 |
| Genovesi, A | 1 |
| Carluccio, M | 1 |
| Krauser, DG | 1 |
| Devereux, RB | 1 |
| Nakashidze, NM | 1 |
| Machavariani, PT | 1 |
| Spark, P | 2 |
| Moullet, C | 2 |
| Lukas, MA | 2 |
| Remme, W | 1 |
| Nessler, J | 1 |
| Nessler, B | 1 |
| Kitliński, M | 1 |
| Libionka, A | 1 |
| Kubinyi, A | 1 |
| Konduracka, E | 1 |
| Piwowarska, W | 1 |
| Kanoupakis, EM | 1 |
| Manios, EG | 1 |
| Mavrakis, HE | 1 |
| Kallergis, EM | 1 |
| Lyrarakis, GM | 1 |
| Koutalas, EP | 1 |
| Vardas, PE | 1 |
| Berruezo, A | 1 |
| Brugada, J | 1 |
| Zehender, M | 1 |
| Just, H | 1 |
| Fesmire, SI | 1 |
| Marcoux, LG | 1 |
| Lyyski, DS | 1 |
| Sprague, MK | 1 |
| Kennedy, HL | 1 |
| Eichhorn, EJ | 1 |
| Packer, M | 1 |
| Correia, JM | 1 |
| Cosín Aguilar, J | 1 |
| Hernándiz Martínez, A | 1 |
| Nägele, H | 1 |
| Schomburg, R | 1 |
| Petersen, B | 1 |
| Rödiger, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Controlled Trial of Influenza Vaccine to Prevent Adverse Vascular Events: A Pilot Study[NCT01945268] | Phase 4 | 107 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| A Randomized Controlled Trial of Influenza Vaccine to Prevent Adverse Vascular Events[NCT02762851] | Phase 4 | 5,000 participants (Anticipated) | Interventional | 2016-06-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 reviews available for carvedilol and Cardiac Arrest, Sudden
| Article | Year |
|---|---|
[Treatment of heart failure: an update].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antidiuretic Hormone Receptor | 2002 |
[Congestive heart failure and acute myocardial infarction: latest trials with beta-blocking agents].
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; | 2002 |
Carvedilol: beta-blockade and beyond.
Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Carbazoles; Carvedilol; Clinical Trials as Topic; | 2004 |
Drug and drug-device therapy in heart failure patients in the post-COMET and SCD-HeFT era.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme 2; Anti-Arrhythmia Agents; Carbazoles; Ca | 2005 |
A review of carvedilol arrhythmia data in clinical trials.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprolol; Ca | 2005 |
Ventricular hypertrophy and hypertension: prognostic elements and implications for management.
Topics: Adrenergic Antagonists; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Convert | 2006 |
[Value of beta-blocker therapy in treatment of coronary heart disease and sudden cardiac death with special reference to carvedilol].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Cause of Death; Coronary Disease; Death, Sudden | 1996 |
Current role of beta-adrenergic blockers in the management of chronic heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Carbazoles; Carvedilol; Chron | 2001 |
[Clinical trials on heart failure].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Amiodarone; Angiotensin-Converting Enzyme | 2001 |
8 trials available for carvedilol and Cardiac Arrest, Sudden
| Article | Year |
|---|---|
Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure--COMET.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Death, Sudden, Cardiac; Double-Blind Method; Fe | 2005 |
Drug and drug-device therapy in heart failure patients in the post-COMET and SCD-HeFT era.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme 2; Anti-Arrhythmia Agents; Carbazoles; Ca | 2005 |
[Estimation of effectiveness of the prevention of sudden cardiac death in patients with myocardial infarction].
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Death, Sudden, Cardiac; Female; Humans; Male; M | 2006 |
Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET.
Topics: Adrenergic beta-Antagonists; Angina, Unstable; Carbazoles; Carvedilol; Death, Sudden, Cardiac; Doubl | 2007 |
Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET.
Topics: Adrenergic beta-Antagonists; Angina, Unstable; Carbazoles; Carvedilol; Death, Sudden, Cardiac; Doubl | 2007 |
Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET.
Topics: Adrenergic beta-Antagonists; Angina, Unstable; Carbazoles; Carvedilol; Death, Sudden, Cardiac; Doubl | 2007 |
Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET.
Topics: Adrenergic beta-Antagonists; Angina, Unstable; Carbazoles; Carvedilol; Death, Sudden, Cardiac; Doubl | 2007 |
The safety of amiodarone in patients with heart failure.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; | 2007 |
Sudden cardiac death risk factors in patients with heart failure treated with carvedilol.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Death, Sudden, Cardiac; Female; He | 2007 |
Electrophysiological effects of carvedilol administration in patients with dilated cardiomyopathy.
Topics: Action Potentials; Adrenergic beta-Antagonists; Aged; Blood Pressure; Carbazoles; Cardiomyopathy, Di | 2008 |
Dual chamber pacing in patients with severe heart failure on beta blocker and amiodarone treatment: preliminary results of a randomised study.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Carbazoles; Cardiac Pacing, Artific | 2002 |
11 other studies available for carvedilol and Cardiac Arrest, Sudden
| Article | Year |
|---|---|
Comparison of carvedilol versus metoprolol in patients with acute myocardial infarction: A protocol for systematic review and meta-analysis.
Topics: Arrhythmias, Cardiac; Carvedilol; Death, Sudden, Cardiac; Humans; Meta-Analysis as Topic; Metoprolol | 2021 |
The use of guideline recommended beta-blocker therapy in primary prevention implantable cardioverter defibrillator patients: insight from Danish nationwide registers.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Death, Sudden, Cardiac; Defibrillators, I | 2018 |
Importance of beta-blocker dose in prevention of ventricular tachyarrhythmias, heart failure hospitalizations, and death in primary prevention implantable cardioverter-defibrillator recipients: a Danish nationwide cohort study.
Topics: Adrenergic beta-Antagonists; Aged; Carvedilol; Death, Sudden, Cardiac; Defibrillators, Implantable; | 2018 |
A comparison of anti-arrhythmic efficacy of carvedilol vs metoprolol succinate in patients with implantable cardioverter-defibrillators.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Arkansas; Carvedilol; Cause of Death; Death, Su | 2019 |
Urinary 8-hydroxy-2'-deoxyguanosine as a novel biomarker for predicting cardiac events and evaluating the effectiveness of carvedilol treatment in patients with chronic systolic heart failure.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adrenergic beta-Antagonists; Adult; Aged; Biomarkers; Carbazoles; Carve | 2012 |
COMET: a proposed mechanism of action to explain the results and concerns about dose.
Topics: Adenosine Triphosphatases; Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Carbazoles; Carvedilol | 2003 |
[Correction of baroreflex sensitivity impairment and efficacy of prevention of sudden arrhythmic death in patients with postinfarction left ventricular dysfunction].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti | 2004 |
[Sudden cardiac death: prevention when is right! From evidence-based medicine to family-based medicine].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Carbazoles; Carvedilol; Death, Su | 2006 |
Betablockers: is the reduction of sudden death related to pure electrophysiologic effects?
Topics: Adrenergic beta-Antagonists; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Death, Sudden, Cardiac | 2008 |
Effect of selective versus nonselective beta blockade on QT dispersion in patients with nonischemic dilated cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Death, Su | 1999 |
[Options in drug combinations].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Car | 2001 |